These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
847 related articles for article (PubMed ID: 2434218)
1. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152). Fujimoto K; Oka T; Morimoto M Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice. Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397 [TBL] [Abstract][Full Text] [Related]
3. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778 [TBL] [Abstract][Full Text] [Related]
4. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C. Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076 [TBL] [Abstract][Full Text] [Related]
6. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Kobayashi E; Okamoto A; Asada M; Okabe M; Nagamura S; Asai A; Saito H; Gomi K; Hirata T Cancer Res; 1994 May; 54(9):2404-10. PubMed ID: 8162588 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity. McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436 [TBL] [Abstract][Full Text] [Related]
10. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice. Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799 [TBL] [Abstract][Full Text] [Related]
11. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Watanabe M; Komeshima N; Nakajima S; Tsuruo T Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075 [TBL] [Abstract][Full Text] [Related]
12. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro. Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative. Bradner WT; Rose WC; Schurig JE; Schlein A; Huftalen JB Cancer Res; 1984 Dec; 44(12 Pt 1):5619-23. PubMed ID: 6437670 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative. Bradner WT; Rose WC; Schurig JE; Florczyk AP; Huftalen JB; Catino JJ Cancer Res; 1985 Dec; 45(12 Pt 1):6475-81. PubMed ID: 3933826 [TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide. Burres NS; Clement JJ Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652 [TBL] [Abstract][Full Text] [Related]
16. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent. Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Elliott WL; Roberts BJ; Howard CT; Leopold WR Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790 [TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor activity of bizelesin in mice. Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280 [TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of quinocarmycin (KW2152) against various cultured leukemia and lymphoma cell lines in vitro. Inaba S; Shimoyama M Cancer Res; 1988 Nov; 48(21):6029-32. PubMed ID: 3167853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]